AlaskaDenise
In Memoriam
by ArabianBusiness.com staff writer on Sunday, 01 April 2007
GlaxoSmithKline (GSK) has announced clinical trial data from two new studies, which show that GSK's candidate pre-pandemic split antigen H5N1 vaccine, formulated with GSK's proprietary adjuvant system, provides a substantial level of cross-immunity against a ‘drifted' (diverse) strain of H5N1.
It is hoped that the immune response elicited with this vaccine could help prepare or ‘prime' the immune system to rapidly respond against variants of the H5N1 strain and therefore protect the vaccinated population in the event of an H5N1 human pandemic.
In the first study presented at the ‘IX International Symposium on Respiratory Viral Infections (ISRVI)', data demonstrated that GSK's proprietary adjuvanted candidate pre-pandemic vaccine, containing very low levels of the Vietnam H5N1 antigen, elicits a strong cross-immune neutralising antibody response in humans against the Indonesian strain of the virus. The neutralising antibody seroconversion factor at Day 42 was shown to be 25 times greater when the vaccine contained the adjuvant system compared with that observed in the control group immunised with a non-adjuvanted vaccine (77.1% vs. < 3%).
http://www.arabianbusiness.com/index.php?option=com_content&view=article&id=11095
GlaxoSmithKline (GSK) has announced clinical trial data from two new studies, which show that GSK's candidate pre-pandemic split antigen H5N1 vaccine, formulated with GSK's proprietary adjuvant system, provides a substantial level of cross-immunity against a ‘drifted' (diverse) strain of H5N1.
It is hoped that the immune response elicited with this vaccine could help prepare or ‘prime' the immune system to rapidly respond against variants of the H5N1 strain and therefore protect the vaccinated population in the event of an H5N1 human pandemic.
In the first study presented at the ‘IX International Symposium on Respiratory Viral Infections (ISRVI)', data demonstrated that GSK's proprietary adjuvanted candidate pre-pandemic vaccine, containing very low levels of the Vietnam H5N1 antigen, elicits a strong cross-immune neutralising antibody response in humans against the Indonesian strain of the virus. The neutralising antibody seroconversion factor at Day 42 was shown to be 25 times greater when the vaccine contained the adjuvant system compared with that observed in the control group immunised with a non-adjuvanted vaccine (77.1% vs. < 3%).
http://www.arabianbusiness.com/index.php?option=com_content&view=article&id=11095